Maria Chiara Clementi

Papers

Total Citations

H-Index

About

Dr. Maria Chiara Clementi is a pioneering researcher at the intersection of oncology and biomedical sensor technology, whose work is redefining non-invasive cancer diagnostics. Her primary research focus lies in the development and clinical application of electronic nose (eNose) technology for volatile organic compound (VOC) analysis, particularly in urological malignancies. Dr. Clementi’s most impactful contribution is her landmark 2024 study, "Prostate cancer risk stratification via eNose urine odor analysis: a preliminary report," which has already garnered 3 citations. This work introduces a groundbreaking, non-invasive method to distinguish between low-risk, indolent prostate cancer and aggressive, life-threatening forms by analyzing the odor profile of urine samples. The significance of this approach is profound: it offers a potential solution to the critical clinical challenge of over-treatment in low-risk prostate cancer patients, enabling more precise therapeutic decision-making before any intervention. By bridging advanced sensor technology with clinical urology, Dr. Clementi is paving the way for cost-effective, rapid, and patient-friendly screening tools that could dramatically alter prostate cancer management paradigms. Her innovative research positions her as a rising leader in the field of cancer metabolomics and point-of-care diagnostics.